Tactic Pharma Llc Sells 33,334 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) major shareholder Tactic Pharma Llc sold 33,334 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the transaction, the insider now owns 822,255 shares of the company’s stock, valued at approximately $28,778,925. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Monopar Therapeutics Trading Down 13.3 %

Shares of NASDAQ MNPR opened at $30.00 on Friday. The firm has a market capitalization of $183.39 million, a P/E ratio of -15.23 and a beta of 1.01. The firm’s 50-day moving average price is $38.29 and its 200-day moving average price is $24.88. Monopar Therapeutics Inc. has a 1-year low of $1.72 and a 1-year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($1.87). Equities research analysts forecast that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Institutional Trading of Monopar Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics during the fourth quarter worth $45,000. Geode Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 174.4% in the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after purchasing an additional 24,530 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Monopar Therapeutics during the fourth quarter valued at about $2,861,000. Point72 Asset Management L.P. bought a new stake in Monopar Therapeutics in the 4th quarter worth about $3,694,000. Finally, RA Capital Management L.P. purchased a new stake in Monopar Therapeutics in the 4th quarter valued at about $11,247,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on MNPR. Jones Trading reiterated a “hold” rating on shares of Monopar Therapeutics in a report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $44.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.